Acalabrutinib treated TCL1 transgenic mice showed significant suppression of CLL cell growth and subsequently decreased tumor burden by blocking BCR signaling-mediated PLCγ2 and ERK, proving its in vivo efficacy against CLL [59,60,61]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.